Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Not yet recruiting
1
100.0%
No approval data available
- Clearmind Medicine announced the publication of a patent by the Korean Intellectual Property Office for its innovative MEAI and N-Acylethanolamines combination therapy targeting cocaine addiction. - Preclinical trials demonstrated that MEAI significantly reduced cocaine-seeking behavior without affecting natural reward responses, suggesting its specificity for drug-related compulsions rather than general reward systems. - The patent is part of Clearmind's collaboration with SciSparc Ltd. to develop novel psychedelic-derived therapeutics, combining Clearmind's MEAI with SciSparc's PEA for addiction and mental health treatments.
- Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD). - The trial, to be conducted at Yale School of Medicine, will assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings. - CMND-100 aims to address the critical gap in AUD treatment, where current options have limited efficacy (less than 30%) and patient compliance. - Alcohol consumption causes 2.6 million deaths annually worldwide, highlighting the urgent need for effective AUD treatments.
- Clearmind Medicine has secured IRB approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD). - The multi-center trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 at Johns Hopkins University, Yale School of Medicine, and IMCA Center in Israel. - Clearmind previously obtained FDA approval for its Investigational New Drug (IND) application in the U.S. and approval from the Israeli Ministry of Health. - The trial's primary endpoint is to determine the tolerable dose and assess the safety profile of CMND-100 in healthy volunteers and AUD subjects.
